Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review

Concurrent mutations of epidermal growth factor receptor (EGFR) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in non-small cell lung cancer (NSCLC) are rare, and the presence of concurrent mutations may complicate treatment. Herein, we report a case of primary l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yonghui, Zhang, Kai, Guan, Jiexia, Wu, Weibin, Zhang, Jian, Chen, Huiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437381/
https://www.ncbi.nlm.nih.gov/pubmed/34526820
http://dx.doi.org/10.2147/CMAR.S326094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437381/
https://www.ncbi.nlm.nih.gov/pubmed/34526820
http://dx.doi.org/10.2147/CMAR.S326094

Ejemplares similares